Trial results favor prasugrel over ticagrelor after coronary stenting

Prasugrel reduced major cardiovascular events to the same extent as ticagrelor but with lower major bleeding after coronary stenting in patients with acute coronary syndromes, according to results from the SWITCH SWEDEHEART trial presented in a Hot Line session at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

≈